JP Morgan Chase
AEMD icon

JP Morgan Chase’s Aethlon Medical AEMD Stock Holding History

JP Morgan Chase’s Portfolio AEMD Stock Details AEMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21
Closed -$768 – 7365
2024
Q3 		$768 Buy
+21
New +$667 ﹤0.01% 6751

Other funds holding AEMD

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SCA
Sassicaia Capital Advisers Jericho, New York $88.8M AUM 146.47% 1-Year Est. Return
AFGAS
Allegiance Financial Group Advisory Services Vienna, Virginia $503M AUM 22.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

JP Morgan Chase's AEMD Position: Q4 2024 in Review

JP Morgan Chase sold out of Aethlon Medical (AEMD) in Q4 2024, closing a stake of 21 shares — an estimated $768 sold.

JP Morgan Chase first reported a position in AEMD in Q3 2024 and held it in 1 quarter. The position peaked at $768 in Q3 2024. 20 funds tracked by Wall St. Rank hold AEMD as of Q4 2024.

  • JP Morgan Chase reported no remaining Aethlon Medical position as of Q4 2024 after selling out during the quarter.
  • JP Morgan Chase sold 21 Aethlon Medical shares in Q4 2024, an estimated $768.
  • JP Morgan Chase first reported a position in Aethlon Medical in Q3 2024 and held it in 1 quarter.
  • JP Morgan Chase's Aethlon Medical position peaked at $768 in Q3 2024.
  • 20 funds tracked by Wall St. Rank held Aethlon Medical as of Q4 2024.

Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.